Atherosclerosis and Hyperlipidemia Research
Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.
Atherosclerosis and Hyperlipidemia Research Products Targets
- PI 3-kinase (22)
- HMG-CoA Reductase (8)
- Matrix Metalloprotease (16)
- LXR-like Receptor (6)
- Elastase (1)
- Cell Adhesion Molecule (21)
- Lipoxygenase (8)
- Leukotriene and Related Receptor (13)
- Others (7)
- Cyclooxygenase (24)
- Angiotensin-Converting Enzyme (8)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Urotensin-II Receptor (8)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Cytokine (15)
- Platelet-Activating Factor (PAF) Receptor (5)
Products for Atherosclerosis and Hyperlipidemia Research - Page 2
- Cat.No. Product Name Information/Activity
-
BCC5826
Ac2-12
256447-08-2
-
BCC5825
Ac2-26
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
-
BCC3945
BIO 1211
Selective <span class='symbol'>α</span><sub>4</sub><span class='symbol'>β</span><sub>1</sub> (VLA-4) inhibitor
-
BCC8002
BIO 5192
327613-57-0
-
BCC3942
Cilengitide
Cilengitide, a cyclic RGD-containing peptide, is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50s of 4 and 79 nM, respectively.
-
BCC5988
Echistatin, α1 isoform
154303-05-6
-
BCC6998
GR 144053 trihydrochloride
1215333-48-4
-
BCC5938
KF 38789
257292-29-8
-
BCC6229
LDV FITC
1207610-07-8
-
BCC6332
Leukadherin 1
Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18.
